Development of Disease-modifying Therapies Against Alzheimer's Disease

Overview

Journal Psychiatry Clin Neurosci

Specialties Neurology
Psychiatry

Date 2024 Jun 6

PMID 38842037

Authors

Takeshi Iwatsubo

Affiliations

Soon will be listed here.

Abstract

To successfully develop disease-modifying therapies (DMT) against Alzheimer's disease (AD), it is important to target the mild stage of the disease, before the pathological changes progress and dementia symptoms are fully manifested. To this end, the AD Neuroimaging Initiative (ADNI), a large-scale observational study, was initiated in the U.S. with the goal of development of DMT that are effective in the early stages of mild cognitive impairment (MCI) by utilizing imaging and biomarkers. In Japan, J-ADNI enrolled and followed up 537 patients, mainly with MCI, and established a platform for evaluation including amyloid PET, and demonstrated a high similarity in the clinical course of amyloid-positive MCI (prodromal AD) in Japan and the U.S. In 2023, the anti-Aβ antibody lecanemab successfully completed a Phase III clinical trial for early AD (prodromal AD + mild AD dementia) and was granted regulatory approval and made available both in the US and Japan. Also, phase III trial of donanemab was completed successful. The J-TRC study was initiated in Japan as a "trial ready cohort (TRC)" consisting of participants who met the eligibility criteria for participation in preclinical and prodromal AD trials. Based on such a platform, the development of DMT for AD will progress more rapidly in the future.

References

Niimi Y, Janelidze S, Sato K, Tomita N, Tsukamoto T, Kato T . Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly. Alzheimers Res Ther. 2024; 16(1):115. PMC: 11112892. DOI: 10.1186/s13195-024-01469-w. View

Sperling R, Donohue M, Raman R, Rafii M, Johnson K, Masters C . Trial of Solanezumab in Preclinical Alzheimer's Disease. N Engl J Med. 2023; 389(12):1096-1107. PMC: 10559996. DOI: 10.1056/NEJMoa2305032. View

Sevigny J, Chiao P, Bussiere T, Weinreb P, Williams L, Maier M . The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016; 537(7618):50-6. DOI: 10.1038/nature19323. View

Mummery C, Borjesson-Hanson A, Blackburn D, Vijverberg E, De Deyn P, Ducharme S . Tau-targeting antisense oligonucleotide MAPT in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2023; 29(6):1437-1447. PMC: 10287562. DOI: 10.1038/s41591-023-02326-3. View

van Dyck C, Swanson C, Aisen P, Bateman R, Chen C, Gee M . Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2022; 388(1):9-21. DOI: 10.1056/NEJMoa2212948. View

Doody R, Thomas R, Farlow M, Iwatsubo T, Vellas B, Joffe S . Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370(4):311-21. DOI: 10.1056/NEJMoa1312889. View

Swanson C, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai R . A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021; 13(1):80. PMC: 8053280. DOI: 10.1186/s13195-021-00813-8. View

Egan M, Kost J, Voss T, Mukai Y, Aisen P, Cummings J . Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. N Engl J Med. 2019; 380(15):1408-1420. PMC: 6776078. DOI: 10.1056/NEJMoa1812840. View

Teng E, Manser P, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S . Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2022; 79(8):758-767. PMC: 9194753. DOI: 10.1001/jamaneurol.2022.1375. View

10.

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A . Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008; 372(9634):216-23. DOI: 10.1016/S0140-6736(08)61075-2. View

11.

Nilsberth C, Westlind-Danielsson A, Eckman C, Condron M, Axelman K, Forsell C . The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001; 4(9):887-93. DOI: 10.1038/nn0901-887. View

12.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T . Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999; 400(6740):173-7. DOI: 10.1038/22124. View

13.

Doody R, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S . A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013; 369(4):341-50. DOI: 10.1056/NEJMoa1210951. View

14.

Sperling R, Salloway S, Brooks D, Tampieri D, Barakos J, Fox N . Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012; 11(3):241-9. PMC: 4063417. DOI: 10.1016/S1474-4422(12)70015-7. View

15.

Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S . Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci. 2009; 29(36):11393-8. PMC: 6665926. DOI: 10.1523/JNEUROSCI.2021-09.2009. View

16.

Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K . Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimers Dement. 2018; 14(8):1077-1087. DOI: 10.1016/j.jalz.2018.03.009. View

17.

Sims J, Zimmer J, Evans C, Lu M, Ardayfio P, Sparks J . Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023; 330(6):512-527. PMC: 10352931. DOI: 10.1001/jama.2023.13239. View

18.

Budd Haeberlein S, Aisen P, Barkhof F, Chalkias S, Chen T, Cohen S . Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. J Prev Alzheimers Dis. 2022; 9(2):197-210. DOI: 10.14283/jpad.2022.30. View

19.

DeMattos R, Lu J, Tang Y, Racke M, Delong C, Tzaferis J . A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron. 2012; 76(5):908-20. DOI: 10.1016/j.neuron.2012.10.029. View